Ernexa Therapeutics Inc - 31 (ERNAW) Institutional Buying & Selling Tracker (Q2 2026)

ERNAW ranks #11354 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

6 institutions disclose a position in ERNAW, but none treat it as a major bet — even Bleichroeder LP, its most concentrated holder, allocates just 0.0% of its own portfolio to it.

ERNAW reported a net loss of $12.3M over the trailing twelve months.

• Not yet profitable — net loss of $12.3M over the trailing twelve months
• Revenue grew 755.9% year over year
• Net income improved year over year, from -$43.7M to -$12.3M
• Operating cash flow was negative, using $7.0M in cash
• Current ratio of 1.01x — below the conventional 1.5x liquidity buffer
• Liabilities run 88.03x equity — a highly leveraged balance sheet worth noting